Stuttgart
08.01.26 | 20:32
4,940 Euro
+1,23 % +0,060
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,900 | 5,050 | 20:49 | |
| 4,900 | 5,050 | 20:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Silence Therapeutics beruft CFO Rhonda Hellums in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 15.12.25 | Silence Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | Silence Therapeutics Announces Leadership Changes | 1 | City A.M. | ||
| 15.12.25 | Silence Therapeutics CEO Craig Tooman steps down | 1 | Investing.com | ||
| 15.12.25 | Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis | 4 | Seeking Alpha | ||
| 12.11.25 | Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 6 | City A.M. | ||
| 12.11.25 | Silence Therapeutics plc: Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 334 | Business Wire | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat... ► Artikel lesen | |
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | Silence Therapeutics: EPS übertrifft Schätzungen um 0,04 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 06.11.25 | Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M | 2 | Seeking Alpha | ||
| 06.11.25 | Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 4 | City A.M. | ||
| 06.11.25 | Silence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 420 | Business Wire | SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
Silence Therapeutics plc, Nasdaq:... ► Artikel lesen | |
| 06.11.25 | Silence Therapeutics plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11.25 | Silence Therapeutics plc - 8-K, Current Report | 2 | SEC Filings | ||
| 23.10.25 | Silence Therapeutics plc - 8-K, Current Report | 5 | SEC Filings | ||
| 23.10.25 | Silence Therapeutics completes enrollment in PV treatment study | 3 | Investing.com | ||
| 23.10.25 | Silence Therapeutics plc: Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) | 330 | Business Wire | Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26
Silence Therapeutics plc (Nasdaq: SLN), a global... ► Artikel lesen | |
| 02.09.25 | Silence Therapeutics plc: Silence Therapeutics to Participate in September Investor Conferences | 433 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate... ► Artikel lesen | |
| 07.08.25 | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.08.25 | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 396 | Business Wire | Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV
SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025
Silence... ► Artikel lesen | |
| 07.08.25 | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 49,510 | +2,05 % | Achtung Anschnallen! 2026 wird zum Raketen-Start für Novo Nordisk, Evotec, Bayer und Vidac Pharma | Die Börse startet mit guter Laune ins neue Jahr 2026. Dass man nicht nur mit Tech-Aktien Geld verdienen kann, zeigte der Minen- und Rohstoffsektor, wo sich nahezu jeder Wert verdoppeln konnte und auch... ► Artikel lesen | |
| GILEAD SCIENCES | 103,18 | -3,10 % | GSK: Erfolg in Hepatitis B - wird Gilead nun abgehängt? | GlaxoSmithKline hat positive Ergebnisse aus den beiden entscheidenden Phase-3-Studien seines experimentellen Medikaments Bepirovirsen zur Behandlung von chronischer Hepatitis B vorgelegt. Noch im laufenden... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 406,70 | -1,87 % | $100 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth This Much Today | ||
| INNOCAN PHARMA | 5,050 | +3,06 % | Innocan Pharma Corporation plant Listing an der NYSE American Stock Exchange mit gleichzeitigem Emissionsangebot | Herzliya, Israel und Calgary, AB - 2. Januar 2026 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) (das "Unternehmen" oder "Innocan"), ein
pharmazeutisches Technologieunternehmen... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 71,00 | -0,31 % | GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies | ||
| SNDL | 1,406 | -0,85 % | 1CM Inc.: SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan | Edmonton, Alberta and Toronto, Ontario--(Newsfile Corp. - January 7, 2026) - SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) ("SNDL") and 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) ("1CM") are pleased... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 25,400 | -5,22 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,320 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness Announces Grand Opening of Its 31st Location in Red Deer, Alberta | Toronto, Ontario--(Newsfile Corp. - January 8, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 361,70 | 0,00 % | Bernstein senkt Kursziel für Alnylam wegen schwächerer Amvuttra-Umsätze | ||
| LIGAND PHARMACEUTICALS | 168,00 | +2,44 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,010 | 0,00 % | Promino Nutritional Sciences, Inc.: Promino Announces Secured Convertible Debenture Offering for Proceeds of up to $1 Million | Burlington, Ontario--(Newsfile Corp. - December 9, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces it intends to complete a non-brokered... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 12,800 | -3,03 % | Raymond James raises WAVE Life Sciences stock price target to $26 | ||
| DARE BIOSCIENCE | 2,045 | +3,81 % | Dare Bioscience, Inc. - 8-K, Current Report | ||
| HYTN INNOVATIONS | 0,114 | 0,00 % | HYTN begrüßt US-Präsidialverordnung zur Einstufung von Cannabis in Schedule III | Vancouver, British Columbia - 18. Dezember 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
Hersteller von Cannabis in pharmazeutischer... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 0,625 | -3,10 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Provides Corporate Update Following Recent Financing | Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma... ► Artikel lesen |
Das Unternehmen SILENCE THERAPEUTICS PLC ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,23 % bei einem Aktienkurs von 4,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.